Data Collection
Research cardiologists and specialized research nurses recorded data concerning sociodemographic variables, medical history, therapeutic procedures, and clinical events during the patient's stay in the hospital. Information was obtained from the hospital medical records and by direct interview with the patient, family members, and the treating physician. After each patient gave written informed consent to enter the OACIS, all in-hospital data were transmitted to the data collection center located in the Department of Internal Medicine and Therapeutics in Osaka University Graduate School of Medicine for processing and analysis.
We obtained follow-up clinical data at 3, 6, and 12 months after the onset of AMI and annually thereafter in survivors. We obtained data concerning subsequent cardiac events by visits to the research outpatient clinic or, in a few instances, by verbal or written contact with the patient's physician, the patient, or family members.
Quality Control
Before initiation of this study, a research cardiologist and specialized research nurse at each site received a training manual that explained how to complete the case report form, defined each variable, and provided examples of correct responses. Double-key entry was used by the data collection center to add each case report form to the database. Audits were performed electronically to detect outof-range variables, inconsistencies, errors, or omissions. Then telephone contact was made with the local research cardiologists and specialized research nurses for resolution of any problems.
Smoking Status
Smoking status was assessed at baseline on the basis of information obtained from the hospital medical records and by direct interview with the patient, family members, and the treating physician and then at 3 months after hospital discharge on the basis of information provided by a mailed questionnaire. Patients were divided into 4 groups: nonsmokers, defined as patients who had never smoked cigarettes regularly; former smokers, those who had stopped smoking before the onset of AMI; quitters, those who stopped smoking after the onset of AMI; and persistent smokers, those who smoked before and after the onset of AMI.
Statistical Analysis
The differences in continuous variables between groups were tested by one-way analysis of variance with Bonferroni post hoc test. Categorical variables were compared by the chi-square test. Variables incorporated into our analysis included characteristics previously identified as factors of well-known prognostic importance, including age, gender, body mass index, diabetes mellitus, hypertension, hyperlipidemia, prior myocardial infarction (MI), prior angina pectoris, prior cerebrovascular disease, systolic blood pressure <100 mmHg on admission, heart rate ≥100 beats/min on admission, Killip class, anterior wall MI, atrial fibrillation/flutter, ventricular fibrillation/flutter, revascularization, medication at discharge (ie, angiotensin-converting enzyme (ACE) inhibitor, -blocker, HMG-CoA reductase inhibitor, or antiplatelet agent), and hospital characteristics (ie, no. of percutaneous coronary intervention (PCI) >200 procedures/year, no. of beds >200, or AMI case load >50 patients/year). A multiple logistic regression model was used to analyze factors influencing persistent smoking in patients who were smokers at the time of the incident AMI. Survival curves were constructed by the Kaplan-Meier method and differences in survival were assessed using the log-rank test. Cox regression analysis was used for assessing the relative hazard of events. Analyses of data were performed using statistical software, version 11.0 (SPSS Japan Inc, Tokyo, Japan). For all analyses, significance was defined as p<0.05.
Results

Baseline Characteristics
Of the 4,035 AMI patients who were still alive 3 months after hospital discharge, 2,579 completed the 3-month smoking status study. At the time of the incident AMI, 823 patients (31.9%) were nonsmokers, 332 patients (12.9%) were former smokers, and 1,424 patients (55.2%) were current smokers. Of the 1,424 current smokers, 1,056 (74.2%) had quit smoking and 368 patients (25.8%) were persistent smokers at 3 months after hospital discharge. Table 1 shows the baseline characteristics of the study populations. Nonsmokers were older and there was a higher prevalence of women, hypertension, anterior wall MI, atrial fibrillation/flutter, and a higher Killip classes. They were less likely to be treated with reperfusion therapy and ACE inhibitor. The multiple logistic regression model used to analyze factors influencing continuing smoking in patients who were smokers at the time of the incident MI identified younger age and prior MI as independent predictive factors of persistent smokers ( Table 2) .
Effect of Smoking Status on Long-Term Mortality
In the unadjusted Cox regression analysis (Table 3) , quitters had lower risks of death from all causes than nonsmokers. After adjustment for age, gender, body mass index, diabetes mellitus, hypertension, hyperlipidemia, prior MI, prior angina pectoris, prior cerebrovascular disease, systolic blood pressure <100 mmHg, heart rate ≥100 beats/min, Killip class ≥2, anterior wall MI, atrial fibrillation/flutter, ventricular fibrillation/flutter, revascularization, use of ACE inhibitors, -blockers, HMG-CoA reductase inhibitor, and antiplatelet agents, performance of PCI >200 procedures/year, no. of beds >200, and AMI case load >50 patients/year, persistent smokers had a greater risk of death from all causes than nonsmokers. The hazard ratio for long-term mortality in the quitters was low, equivalent to nonsmokers. To assess the effect of smoking cessation on long-term mortality, we examined the risk of death from all causes in quitters and compared it with the risk in persistent smokers. Fig 1 shows the Kaplan-Meier survival curves for long-term mortality in quitters vs persistent smokers. Quitters had lower long-term all-cause mortality than persistent smokers (3.0% vs 5.2%; log rank, p=0.032). After adjustment for the previously described variables, smoking cessation was independently associated with a reduction in risk of long-term mortality among patients with AMI (hazard ratio, 0.39; 95% confidence interval (CI): 0.20-0.77).
Discussion
It is established that cigarette smoking is a major risk factor for coronary artery disease and AMI, [1] [2] [3] [4] and there are several plausible mechanisms for the relation of smoking with worse outcome in patients with AMI. Smoking is associated with increased fibrinogen concentrations, 18 increased platelet aggregability, 19 reduced fibrinolytic activity, 20 reduced coronary flow or collateral flow reserve, 21, 22 increased coronary vasoreactivity, 23 and increased myocardial irritability. 24 However, because the risk of cigarette smoking seems to be reversible, quitting is thought to reduce the recurrent adverse events after AMI. 25 Furthermore, quitters comply more closely with medication schedules and the recommended lifestyle changes than do persistent smokers, 26 which are also beneficial effects of smoking cessation on long-term mortality after AMI. In fact, the cessation of smoking after AMI has been shown in Western countries to have a beneficial effect on the recurrent adverse events. [5] [6] [7] [8] [9] [10] [11] A recent meta-analysis showed that quitting smoking is associated with reduced risk of total mortality and the pooled crude relative risk was 0.64 (95%CI: 0.58-0.71). 12 In Japan, it has been reported that smoking cessation is associated with reduced second cardiac events (ie, cardiac death and nonfatal MI) in 90 male patients with a history of MI, 27 but that study had the limitations of small sample size, male subjects only and a combined endpoint. Therefore, we examined the impact of smoking cessation on long-term mortality in Japanese AMI patients using a large hospital-based cohort of patients and found that quitters had lower long-term all-cause mortality rates than persistent smokers and a 61% reduction in longterm mortality after AMI. Our findings, which are derived from a large-scale sample, suggest that smoking cessation is associated with reduction in mortality in Japanese patients with AMI. Numerous randomized control trials have established that several therapies reduce the long-term mortality in patients with AMI (ie, ACE inhibitors, -blockers, aspirin, and HMG-CoA reductase inhibitors). The reduction in long-term mortality after AMI with the use of ACE inhibitors has been shown to be 23%; 28 23% with -blockers; 29 15% with aspirin; 30 and 29% with HMG CoA reductase inhibitors. 31 The benefit of smoking cessation (61% reduction) appears at least as great as these secondary preventive therapies. Our results suggest that smoking cessation is as effective or more effective for reducing mortality as established secondary preventive therapies. Furthermore, evidence from Western countries had shown that quitting smoking after AMI has considerable economic benefits. 32 In the present study, 74.2% of patients had quit smoking at 3 months after hospital discharge. Other studies have reported that the smoking cessation rate is 42-71% within 6 months after hospital discharge. 12, 33, 34 Although it is difficult to make a simple comparison between present and previous studies, the rate of smoking cessation in our study seems to be equivalent to that in previous studies. However, it has been reported that 70% of the patients stopped smoking 3 months after AMI, but one-third had resumed smoking after 4 years. 34 Therefore, smoking cessation rates in the present study population may decrease after a few years. Smoking cessation interventions have been shown to increase the number of quitters after AMI, but brief interventions are ineffective compared with those initiated during initial hospitalization and accompanied by extended outpatient follow-up. 35, 36 Therefore, long-term cessation interventions may increase long-term smoking cessation rates and decrease the long-term mortality in our study population.
Although persistent smoking was an independent predictor of long-term mortality, in patients with a prior MI, persistent smokers had higher long-term mortality rates than quitters (16.7% vs 3.7%; log rank, p=0.002), but in patients with their first MI, long-term mortality did not differ between persistent smokers and quitters (3.2% vs 3.1%; log rank, p=0.470). Therefore, because a prior MI is an independent predictor of persistent smoking, the recurrence of MI may cause a higher mortality rate in persistent smokers. In fact, a subsequent cardiac event may be fatal because of the severe cardiac dysfunction in patients with a prior MI. Furthermore, patients with a prior MI may be more susceptible to the influence of persistent smoking on mortality than those with a first MI. However, quitting smoking in patients with a prior MI was associated with a reduction of risk in long-term mortality to the same level as patients with a first MI. Therefore, rigorous smoking cessation intervention is required for smokers with a prior MI.
Although randomized control trials are necessary to determine the effect of smoking cessation on long-term mortality after AMI, there are a number of problems associated with the ethics and compliance involved in the random assignment of patients to continue or quitting smoking. In Western countries, smoking cessation counsel- ing has been shown to increase smoking cessation rates and to decrease a mortality rates after AMI. 35, 36 Further studies are needed to determine the effect of counseling on smoking cessation and mortality rates after AMI in Japan.
Study Limitations
First, because we did not assess the quit date, number of cigarettes smoked per day, and type of smoking, we were not able to determine the relationship of the duration of cessation and smoking reduction to mortality after AMI. Second, there may have been other factors interrelated with smoking behavior that we did not record; for example, social and educational status were not recorded, although differences in either status are very small in Japan. Finally, smoking status was assessed by a self-reported mailed questionnaire and we did not check the smoking behavior by biochemical validation. However, self-reported smoking habits have been found to be accurate in studies of different populations. 37 Therefore, the influence of misclassification of smoking status on the interpretation of our results was probably limited.
Conclusions
Persistent smoking is associated with an increased longterm mortality after AMI. However, in patients who quit smoking after AMI, the risk became equivalent to that of nonsmokers. These results support efforts to make smoking cessation after AMI an important goal for both patients and physicians.
